The NanoMedicines Innovation Network (NMIN) is pleased to introduce the inaugural members of its Highly Qualified Personnel (HQP) Program Advisory Committee (HPAC). The HQP Program Advisory Committee advises the Research Management Committee (RMC) of NMIN on training and programming opportunities that will increase the knowledge, skills and expertise of trainees… Read More »Meet NMIN’s HQP Program Advisory Committee (HPAC)
NMIN HQP Morgan Alford has been named a 2020 Vanier Canada Graduate Scholarship recipient. Morgan is a PhD candidate supervised by NMIN researcher Dr. Robert Hancock at the University of British Columbia, and is a member of the Executive Committee (Communications Director) of the NMIN HQP Network (NHN). Her research… Read More »NMIN trainee awarded Vanier Scholarship
The NanoMedicines Innovation Network (NMIN) is pleased to introduce the inaugural Executive Committee of its Highly Qualified Personnel (HQP) Network – the NMIN HQP Network (NHN). The NHN Executive Committee is comprised entirely of NMIN HQP, and plays a leadership role in the planning and realization of NMIN’s HQP programs,… Read More »Announcing the NMIN HQP Network Leadership Team
NMIN research co-leader Dr. Christan Kastrup and his research team find that soil silicates play a key role in blood clotting Research led by Dr. Christian Kastrup and published in Blood Advances has found that soil silicates in wounds help activate a blood known as protein coagulation Factor XII. This… Read More »Soil stops bleeding: NMIN researcher
The NanoMedicines Innovation Network (NMIN) is pleased to announce the recipients of its inaugural NMIN Postdoctoral Awards: Dr. Noorjahan Aibani and Dr. Jayesh Kulkarni. Details about both recipients and their research plans follow below. The awardees were selected by the members of NMIN’s Research Management Committee, based on the applicants’… Read More »Inaugural NMIN Postdoctoral Award winners announced
NMIN has granted Strategic Initiative funding to kick-start an effort to develop nanomedicines to fight COVID-19. NMIN’s Scientific Director Dr. Pieter Cullis leads this initiative, which is exploring the use of lipid nanoparticle (LNP) formulations of mRNA as therapeutics and vaccines for CVID-19. “In collaboration with industry partners, this project… Read More »NMIN seed-funds COVID-19 therapeutics project
In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to the evolution of gene therapy. https://www.youtube.com/watch?v=ERU-3b6YtUkThe interview was conducted on behalf of the Gene Delivery and Gene Editing focus group… Read More »The Ins & Outs of Gene Therapy Drug Development: an interview with NMIN’s Scientific Director
Research by NMIN research leader Dr. Marcel Bally and team at Cuprous Pharmaceuticals is featured on the cover of the February 2020 issue of Drug Delivery and Translational Research. The article, Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use, discusses the benefits brought to quercetin by Cuprous’ Metaplex… Read More »NMIN research leader’s finding selected as journal’s feature article
On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR). The approval of ONPATTRO™ has opened the door to a new era of gene therapies to treat most human diseases—including… Read More »“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology
On August 21, 2019, the Board of Directors approved NMIN’s initial investments of $4.3M in nanomedicines research. Over a two-year period, NMIN will support 20 innovative projects led by Canadian leaders in nanomedicine drug delivery, gene therapy and diagnostics. These projects, hosted at six research centres across Canada, span a… Read More »NMIN releases first round of Research Investment